May 30, 2025 07:00 AM EDT

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Biotech Correspondent

→ Allyson McMillan-Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit’s disappointing survival readout raises stakes for full data

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

From weeks to days: how Aizon Intelligent Agents transform pharma validation

An­oth­er Bris­tol My­ers ex­ec goes to Aca­dia; David South­well takes CEO job at ARCH-backed can­cer biotech

Copy Chief

Editor

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech